Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation

Status Recruiting

Clinical Trial Summary

Clinical Trial Description

The effects of haploidentical rhG-CSF-mobilized unmanipulated blood and marrow transplantation (HBMT) on hematological malignancies are well established.The aim of this prospective cohort trial is to determine if acute graft-versus-host disease (aGVHD) could be decreased with IL2 therapy post HBMT.low dose of IL-2 (40 million U/m2) will be administered from WBC engraftment to day 90 post haploidentical transplantation. IL-2 will be administered three times a week. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02659657
Study type	Interventional
Source	Peking University People's Hospital
Contact	Xiangyu Zhao
Phone	+861088324576
Email	zhao_xy@bjmu.edu.cn
Status	Recruiting
Phase	Phase 2
Start date	March 2015
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02241018` - MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD	Phase 2/Phase 3
Completed	`NCT04539470` - Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Phase 1
Terminated	`NCT02245412` - A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease	Phase 2
Completed	`NCT03497273` - Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects	Phase 1
Completed	`NCT05825833` - Infliximab Efficacy in Relation to Therapeutic Drug Monitoring and Serum TNFα Levels in Pediatric HSCT
Not yet recruiting	`NCT06294691` - Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases	Phase 3
Not yet recruiting	`NCT06294678` - Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies	Phase 3
Recruiting	`NCT04285424` - FMT for Steroid Resistant Gut Acute GVHD	Early Phase 1
Terminated	`NCT01903473` - Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)	Phase 2
Recruiting	`NCT02044185` - Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation	N/A
Recruiting	`NCT01765634` - Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease	Phase 2
Terminated	`NCT00282503` - Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease	Phase 3
Recruiting	`NCT01521039` - Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease
Terminated	`NCT03721965` - Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects	Phase 1/Phase 2
Not yet recruiting	`NCT04971551` - A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.	Phase 2
Completed	`NCT02743351` - Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT06394895` - Donor Neutrophil Subsets to Predict the Risk of aGVHD
Terminated	`NCT05673876` - A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)	Phase 1
Recruiting	`NCT02611180` - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease